NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
6
SURI Quote, Financials, Valuation and Earnings
Last price:
$15.70
Seasonality move
:
21.76%
Day range:
$16.54 - $16.81
52-week range:
$16.42 - $27.52
Dividend yield:
19.9%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
729
Avg. volume:
4K
1-year change:
-18.57%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
$16.54 | -- | -- | -- | $0.68 | 19.9% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$60.26 | -- | -- | -- | $0.00 | 0% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$12.09 | -- | -- | -- | $0.00 | 0% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$26.98 | -- | -- | -- | $0.13 | 1.66% | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
$90.63 | -- | -- | -- | $0.09 | 0.34% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$43.42 | -- | -- | -- | $0.19 | 1.61% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | 1.741 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.316 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 2.118 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 1.073 | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.413 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 1.021 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Simplify Propel Opportunities ETF vs. Competitors
-
Which has Higher Returns SURI or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About SURI or BBP?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is SURI or BBP More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.32%.
-
Which is a Better Dividend Stock SURI or BBP?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 19.9%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or BBP?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns SURI or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About SURI or CNCR?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is SURI or CNCR More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.71%.
-
Which is a Better Dividend Stock SURI or CNCR?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 19.9%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or CNCR?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
-
Which has Higher Returns SURI or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About SURI or FTXH?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is SURI or FTXH More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.157%.
-
Which is a Better Dividend Stock SURI or FTXH?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 19.9%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.66% to investors and pays a quarterly dividend of $0.13 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or FTXH?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns SURI or XHS?
SPDR S&P Health Care Services ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About SURI or XHS?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 XHSSPDR S&P Health Care Services ETF0 0 0 -
Is SURI or XHS More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.019, suggesting its more volatile than the S&P 500 by 1.88%.
-
Which is a Better Dividend Stock SURI or XHS?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 19.9%. SPDR S&P Health Care Services ETF offers a yield of 0.34% to investors and pays a quarterly dividend of $0.09 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or XHS?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns SURI or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About SURI or XPH?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is SURI or XPH More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.759, suggesting its less volatile than the S&P 500 by 24.059%.
-
Which is a Better Dividend Stock SURI or XPH?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 19.9%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.61% to investors and pays a quarterly dividend of $0.19 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or XPH?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 6.33% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 14.95% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.81% over the past day.
